Main content



Loading wiki pages...

Wiki Version:
## Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia <br> **Abstract** In 2015, as part of the Reproducibility Project: Cancer Biology, we published a Registered Report ([Fung et al., 2015][1]), that described how we intended to replicate selected experiments from the paper "Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia" ([Dawson et al., 2011][2]). Here we report the results of those experiments. We found that treatment of MLL-fusion leukaemia cells (MV4;11 cell line) with the BET bromodomain inhibitor I-BET151 resulted in selective growth inhibition that was not observed in leukaemia cells harboring a different oncogenic driver (K-562 cell line), similar to those reported in the original study (Figure 2A and Supplementary Figure 11A,B; [Dawson et al., 2011][3]). Further, I-BET151 resulted in a statistically significant decrease in *BCL2* expression in MV4;11 cells, but not K-562 cells, similar to the original study (Figure 3D; [Dawson et al., 2011][4]). We did not find a statistically significant difference in survival when testing I-BET151 efficacy in a disseminated xenograft MLL mouse model, whereas the original study reported an increase in survival in I-BET151 treated mice compared to vehicle control (Figure 4B,D; [Dawson et al., 2011][5]). Monitoring the extent of disease burden in this mouse model, we found I-BET151 treatment resulted in a lower median disease burden compared to vehicle control in all tissues analyzed, similar to the example reported in the original study (Supplementary Figure 16A; [Dawson et al., 2011][6]). Importantly, deviations in this replication attempt compared to the original study, such as a different conditioning regimen and a decreased I-BET151 dose, are factors that might have influenced the outcome. Finally, we report meta-analyses for each result. ---------- ## Contents <br> **Reports**: Read the [Replication Study][18], or view the [preprint versions][7] To reproduce the manuscript text run this in [R Studio][8] (note: downloads [R markdown file][9] directly from library(httr) library(rmarkdown) GET("", write_disk("Replication_Study_29.Rmd", overwrite = T)) render("Replication_Study_29.Rmd", output_format = "word_document") Also, explore the [Registered Report][10] and materials related to the Registered Report [here][11]. <br> **Experiments replicated**: Reproduce and explore the figures, analyses, data, and methods generated in this replication attempt. - [Evaluating the selective inhibition of a MLL-fusion leukemic cell line with I-BET151][12] - Replication of Figure 2A and Supplementary Figure 11A,B in Dawson et al., 2011. - [Analysis of *BCL2* gene expression following I-BET151 treatment][13] - Replication of Figure 3D in Dawson et al., 2011. - [Assessment of maximum tolerated dose of I-BET151 in xenograft MLL mouse model][14] and [Generation of disseminated xenograft MLL mouse model and testing of I-BET151 compound *in vivo*][15] - Replication of Figure 4B,D and Supplementary Figure 16A in Dawson et al., 2011. <br> **Meta-Analysis**: As a measure of evaluating reproducibility, a meta-analysis of each effect was performed. The forest plots, analyses, and data are available [here][16]. <br> Questions about the project can be directed to [][17]. ---------- [1]: [2]: [3]: [4]: [5]: [6]: [7]: [8]: [9]: [10]: [11]: [12]: [13]: [14]: [15]: [16]: [17]: [18]:
OSF does not support the use of Internet Explorer. For optimal performance, please switch to another browser.
This website relies on cookies to help provide a better user experience. By clicking Accept or continuing to use the site, you agree. For more information, see our Privacy Policy and information on cookie use.

Start managing your projects on the OSF today.

Free and easy to use, the Open Science Framework supports the entire research lifecycle: planning, execution, reporting, archiving, and discovery.